Research programme: antibody therapeutics - Innate Pharma/INSERM
Latest Information Update: 16 Jul 2016
At a glance
- Originator Innate Pharma; INSERM
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in France (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in France (Parenteral)